Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 801,958
  • Shares Outstanding, K 85,224
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,850 K
  • EBIT $ -147 M
  • EBITDA $ -154 M
  • 60-Month Beta 1.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.12

Options Overview Details

View History
  • Implied Volatility 81.31% ( -0.65%)
  • Historical Volatility 121.03%
  • IV Percentile 17%
  • IV Rank 15.67%
  • IV High 363.77% on 05/15/25
  • IV Low 28.81% on 06/24/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 50
  • Volume Avg (30-Day) 673
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 11,942
  • Open Int (30-Day) 7,349

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.46
  • Number of Estimates 5
  • High Estimate -0.43
  • Low Estimate -0.53
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.65 +94.19%
on 05/19/25
10.07 -10.33%
on 06/06/25
+4.30 (+90.91%)
since 05/16/25
3-Month
3.90 +131.83%
on 04/09/25
10.07 -10.33%
on 06/06/25
+1.12 (+14.16%)
since 03/17/25
52-Week
3.90 +131.83%
on 04/09/25
14.67 -38.45%
on 02/10/25
+1.59 (+21.37%)
since 06/17/24

Most Recent Stories

More News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC : 9.03 (-4.04%)
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

ORIC : 9.03 (-4.04%)
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

ORIC : 9.03 (-4.04%)
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC : 9.03 (-4.04%)
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

ORIC : 9.03 (-4.04%)
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

ORIC : 9.03 (-4.04%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC : 9.03 (-4.04%)
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

ORIC : 9.03 (-4.04%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC : 9.03 (-4.04%)
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC : 9.03 (-4.04%)

Business Summary

ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco,...

See More

Key Turning Points

3rd Resistance Point 9.87
2nd Resistance Point 9.69
1st Resistance Point 9.36
Last Price 9.03
1st Support Level 8.85
2nd Support Level 8.67
3rd Support Level 8.34

See More

52-Week High 14.67
Fibonacci 61.8% 10.55
Fibonacci 50% 9.28
Last Price 9.03
Fibonacci 38.2% 8.01
52-Week Low 3.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar